arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Greenwich LifeSciences, Inc.

GLSI

$14.40 ▲ +0.04 (+0.28%) at close

8 Visible periods

17 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Greenwich LifeSciences, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $194.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -4349.7% ↘

FCF / Share $-0.73 ↘

Trailing P/E —

Price / Book 582.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-19.36M

↓ -11.2% —

FCF / Share Free cash flow per share

$-0.73

↓ -31.2% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -4349.7% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.51x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	-6.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-94.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-13.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-74.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-11.2% Weak ↑ Weak Improving Year-over-year change in net income	-95.8% Weak ↓ Weak Declining Year-over-year change in net income	-13.6% Weak ↑ Weak Improving Year-over-year change in net income	-71.2% Weak ↓ Weak Declining Year-over-year change in net income	-145.3% Weak Weak Year-over-year change in net income	45.6% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	-31.2% Weak Weak Year-over-year change in free cash flow	-10.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.51x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.42x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.09x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-4349.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1533.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-110.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	200.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-314.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-430.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-133.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12842.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	-132.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-985%)	-59.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-495%)	-17.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	-6.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-145%)	253.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1591%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-6.18M	$-4.09M	$-6.99M	$-13.47M	$-27.20M	$-28.66M	$-6.83K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-1.43	$-1.34	$-0.69	$-0.61	$-0.35	—	—	—
Free Cash Flow per Share (USD)	$-0.73	$-0.56	$-0.50	—	—	—	—	—
Book Value per Share (USD)	$0.02	$0.07	$0.52	$1.03	$2.04	$2.18	$-0.16	—
Tangible Book Value per Share (USD)	$0.02	$0.07	$0.52	$1.03	$2.04	$2.18	$-0.16	—
Basic Weighted Avg Shares (shares)	13.53M	13.01M	12.85M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$353.22K	$906.85K	—	—	—	$27.61M	$-1.37M	—
Total Equity (USD)	$353.22K	$908.63K	$6.70M	$13.21M	$26.83M	$27.63M	$-1.35M	$-10.12M

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Income, GAAP (USD)	$-19.36M	$-17.41M	$-8.89M	$-7.83M	$-4.57M	$-1.86M	$-3.43M	—
Operating Cash Flow (USD)	$-9.91M	$-7.27M	$-6.48M	$-6.20M	$-4.29M	$-1.15M	$-293.27K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Greenwich LifeSciences, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare GLSI with peers